This page shows the latest Autolus news and features for those working in and with pharma, biotech and healthcare.
In November last year, gene therapy specialist Orchard Therapeutics raised over $200m, while CAR-T biotech Autolus generated $150m from its IPO in June.
After a $100m initial public offering last year, Autolus is sitting on upwards of $200m ahead of the follow-on financing. ... to raise additional capital in order to develop and commercialize our product candidates,” said Autolus in an filing with the
Safety profile could bring greater market potential. UK biotech Autolus seems to be on track to develop a next generation of safer and equally, if not more, efficacious CAR-T therapies. ... Autolus is hoping that AUTO1 will change that, and its first
Autolus, which raised $150m in its IPO last June.
Industry attracted a record-breaking £2.2bn in investment last year
Roche, Celgene and Autolus.
More from news
Approximately 5 fully matching, plus 9 partially matching documents found.
The founder of KAPital Consulting, Dr Dhingra currently serves on the boards of Exosome Diagnostics as chairman of the board, Advanced Accelerator Applications, Five Prime and Autolus.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
More than 500 CAR-Ts are in development, making competition fierce. Earlier this year Autolus was forced to delay and even discontinue molecules in its CAR-T pipeline due to both ... The clinical data readout for the AUTO5 trial showed that it “may not
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...